-
Je něco špatně v tomto záznamu ?
RIPK1 targeting protects against obesity and atherosclerosis
Y. Sohrabi, H. Reinecke
Trends in endocrinology and metabolism.
2021 ;
32 (7) :
420-422.
[pub] 20210416
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc22012384
- MeSH
- ateroskleróza * prevence a kontrola MeSH
- dieta s vysokým obsahem tuků MeSH
- játra MeSH
- lidé MeSH
- nealkoholová steatóza jater * MeSH
- obezita MeSH
- serin-threoninkinasy interagující s receptory MeSH
- zánět MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing inflammation, lipid synthesis, and inflammasome activation. Targeting RIPK1 may therefore attenuate chronic metabolic disease and would likely be therapeutic.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012384
- 003
- CZ-PrNML
- 005
- 20220506130213.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.tem.2021.03.009 $2 doi
- 035 __
- $a (PubMed)33875327
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sohrabi, Yahya $u Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany; Institutes of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia. Electronic address: yahya.sohrabi@ukmuenster.de
- 245 10
- $a RIPK1 targeting protects against obesity and atherosclerosis / $c Y. Sohrabi, H. Reinecke
- 520 9_
- $a Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing inflammation, lipid synthesis, and inflammasome activation. Targeting RIPK1 may therefore attenuate chronic metabolic disease and would likely be therapeutic.
- 650 12
- $a ateroskleróza $x prevence a kontrola $7 D050197
- 650 _2
- $a dieta s vysokým obsahem tuků $7 D059305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $7 D007249
- 650 _2
- $a játra $7 D008099
- 650 12
- $a nealkoholová steatóza jater $7 D065626
- 650 _2
- $a obezita $7 D009765
- 650 _2
- $a serin-threoninkinasy interagující s receptory $7 D053422
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Reinecke, Holger $u Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany
- 773 0_
- $w MED00004567 $t Trends in endocrinology and metabolism: TEM $x 1879-3061 $g Roč. 32, č. 7 (2021), s. 420-422
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33875327 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130205 $b ABA008
- 999 __
- $a ok $b bmc $g 1789819 $s 1163585
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 32 $c 7 $d 420-422 $e 20210416 $i 1879-3061 $m Trends in endocrinology and metabolism $n Trends endocrinol. metab. $x MED00004567
- LZP __
- $a Pubmed-20220425
